These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 28138003

  • 1. The effects of liraglutide in mice with diet-induced obesity studied by metabolomics.
    Bugáňová M, Pelantová H, Holubová M, Šedivá B, Maletínská L, Železná B, Kuneš J, Kačer P, Kuzma M, Haluzík M.
    J Endocrinol; 2017 Apr; 233(1):93-104. PubMed ID: 28138003
    [Abstract] [Full Text] [Related]

  • 2. Glucagon-like peptide-1 analog liraglutide leads to multiple metabolic alterations in diet-induced obese mice.
    Park S, Oh S, Kim EK.
    J Biol Chem; 2022 Dec; 298(12):102682. PubMed ID: 36356900
    [Abstract] [Full Text] [Related]

  • 3. GLP-1 analogue-induced weight loss does not improve obesity-induced AT dysfunction.
    Pastel E, McCulloch LJ, Ward R, Joshi S, Gooding KM, Shore AC, Kos K.
    Clin Sci (Lond); 2017 Mar 01; 131(5):343-353. PubMed ID: 28049736
    [Abstract] [Full Text] [Related]

  • 4. Liraglutide reduces body weight by upregulation of adenylate cyclase 3.
    Li Z, Liang Y, Xia N, Lai Y, Pan H, Zhou S, Jiang F, He Y.
    Nutr Diabetes; 2017 May 08; 7(5):e265. PubMed ID: 28481334
    [Abstract] [Full Text] [Related]

  • 5. Urinary metabolomic profiling in mice with diet-induced obesity and type 2 diabetes mellitus after treatment with metformin, vildagliptin and their combination.
    Pelantová H, Bugáňová M, Holubová M, Šedivá B, Zemenová J, Sýkora D, Kaválková P, Haluzík M, Železná B, Maletínská L, Kuneš J, Kuzma M.
    Mol Cell Endocrinol; 2016 Aug 15; 431():88-100. PubMed ID: 27164444
    [Abstract] [Full Text] [Related]

  • 6. Short-term effects of glucagon-like peptide 1 (GLP-1) receptor agonists on fat distribution in patients with type 2 diabetes mellitus: an ultrasonography study.
    Morano S, Romagnoli E, Filardi T, Nieddu L, Mandosi E, Fallarino M, Turinese I, Dagostino MP, Lenzi A, Carnevale V.
    Acta Diabetol; 2015 Aug 15; 52(4):727-32. PubMed ID: 25577244
    [Abstract] [Full Text] [Related]

  • 7. Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity.
    Liang Y, Li Z, Liang S, Li Y, Yang L, Lu M, Gu HF, Xia N.
    Nutr Diabetes; 2016 Jan 25; 6(1):e191. PubMed ID: 26807509
    [Abstract] [Full Text] [Related]

  • 8. The key role of a glucagon-like peptide-1 receptor agonist in body fat redistribution.
    Zhao L, Zhu C, Lu M, Chen C, Nie X, Abudukerimu B, Zhang K, Ning Z, Chen Y, Cheng J, Xia F, Wang N, Jensen MD, Lu Y.
    J Endocrinol; 2019 Feb 01; 240(2):271-286. PubMed ID: 30530905
    [Abstract] [Full Text] [Related]

  • 9. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
    Ye X, Qi J, Yu D, Wu Y, Zhu S, Li S, Wu Q, Ren G, Li D.
    J Diabetes Complications; 2017 Apr 01; 31(4):726-734. PubMed ID: 28143735
    [Abstract] [Full Text] [Related]

  • 10. Liraglutide alleviates high-fat diet-induced kidney injury in mice by regulating the CaMKKβ/AMPK pathway.
    Xuan Y, Ding TT, Mao XL, Pang S, He R, Qin L, Yuan JZ.
    Ren Fail; 2024 Dec 01; 46(1):2351473. PubMed ID: 38915241
    [Abstract] [Full Text] [Related]

  • 11. Antiobesity efficacy of GLP-1 receptor agonist liraglutide is associated with peripheral tissue-specific modulation of lipid metabolic regulators.
    Decara J, Arrabal S, Beiroa D, Rivera P, Vargas A, Serrano A, Pavón FJ, Ballesteros J, Dieguez C, Nogueiras R, Rodríguez de Fonseca F, Suárez J.
    Biofactors; 2016 Nov 12; 42(6):600-611. PubMed ID: 27213962
    [Abstract] [Full Text] [Related]

  • 12. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial.
    Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, Filippaios A, Bowers J, Srnka A, Gavrieli A, Ko BJ, Liakou C, Kanyuch N, Tseleni-Balafouta S, Mantzoros CS.
    Diabetologia; 2016 May 12; 59(5):954-65. PubMed ID: 26831302
    [Abstract] [Full Text] [Related]

  • 13. Lipidized PrRP Analog Exhibits Strong Anti-Obesity and Antidiabetic Properties in Old WKY Rats with Obesity and Glucose Intolerance.
    Mráziková L, Hojná S, Vaculová P, Strnad Š, Vrkoslav V, Pelantová H, Kuzma M, Železná B, Kuneš J, Maletínská L.
    Nutrients; 2023 Jan 05; 15(2):. PubMed ID: 36678151
    [Abstract] [Full Text] [Related]

  • 14. Liraglutide induces beige fat development and promotes mitochondrial function in diet induced obesity mice partially through AMPK-SIRT-1-PGC1-α cell signaling pathway.
    Zhou J, Poudel A, Chandramani-Shivalingappa P, Xu B, Welchko R, Li L.
    Endocrine; 2019 May 05; 64(2):271-283. PubMed ID: 30535743
    [Abstract] [Full Text] [Related]

  • 15. Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment.
    Wang L, Li P, Tang Z, Yan X, Feng B.
    Sci Rep; 2016 Sep 16; 6():33251. PubMed ID: 27633081
    [Abstract] [Full Text] [Related]

  • 16. Experimental evidence for the use of CCR2 antagonists in the treatment of type 2 diabetes.
    Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, Walters MJ, Powers JP, Dairaghi DJ, Baumgart T, Seitz LC, Berahovich RD, Schall TJ, Jaen JC.
    Metabolism; 2013 Nov 16; 62(11):1623-32. PubMed ID: 23953944
    [Abstract] [Full Text] [Related]

  • 17. Liraglutide for Type 2 diabetes and obesity: a 2015 update.
    Iepsen EW, Torekov SS, Holst JJ.
    Expert Rev Cardiovasc Ther; 2015 Nov 16; 13(7):753-67. PubMed ID: 26106933
    [Abstract] [Full Text] [Related]

  • 18. Metabolomics Based on MS in Mice with Diet-Induced Obesity and Type 2 Diabetes Mellitus: the Effect of Vildagliptin, Metformin, and Their Combination.
    Tomášová P, Bugáňová M, Pelantová H, Holubová M, Šedivá B, Železná B, Haluzík M, Maletínská L, Kuneš J, Kuzma M.
    Appl Biochem Biotechnol; 2019 May 16; 188(1):165-184. PubMed ID: 30393821
    [Abstract] [Full Text] [Related]

  • 19. Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker Diabetic Fatty Rats.
    Trevaskis JL, Sacramento CB, Jouihan H, Ali S, Le Lay J, Oldham S, Bhagroo N, Boland BB, Cann J, Chang Y, O'Day T, Howard V, Reers C, Winzell MS, Smith DM, Feigh M, Barkholt P, Schreiter K, Austen M, Andag U, Thompson S, Jermutus L, Coghlan MP, Grimsby J, Dohrmann C, Rhodes CJ, Rondinone CM, Sharma A.
    Diabetes; 2017 Jul 16; 66(7):2007-2018. PubMed ID: 28408435
    [Abstract] [Full Text] [Related]

  • 20. Hypoglycemic and hypolipidemic effects of processed Aloe vera gel in a mouse model of non-insulin-dependent diabetes mellitus.
    Kim K, Kim H, Kwon J, Lee S, Kong H, Im SA, Lee YH, Lee YR, Oh ST, Jo TH, Park YI, Lee CK, Kim K.
    Phytomedicine; 2009 Sep 16; 16(9):856-63. PubMed ID: 19303272
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.